| Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose … D Thaci, EL Simpson, LA Beck, T Bieber, A Blauvelt, K Papp, W Soong, ... The Lancet 387 (10013), 40-52, 2016 | 620 | 2016 |
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and … KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ... The Lancet 392 (10148), 650-661, 2018 | 600 | 2018 |
| Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis KA Papp, A Blauvelt, M Bukhalo, M Gooderham, JG Krueger, JP Lacour, ... New England Journal of Medicine 376 (16), 1551-1560, 2017 | 524 | 2017 |
| Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma HJ Sharpe, G Pau, GJ Dijkgraaf, N Basset-Seguin, Z Modrusan, ... Cancer cell 27 (3), 327-341, 2015 | 402 | 2015 |
| Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) A Blauvelt, JC Prinz, AB Gottlieb, K Kingo, H Sofen, M Ruer‐Mulard, ... British Journal of Dermatology 172 (2), 484-493, 2015 | 373 | 2015 |
| Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis H Sofen, S Smith, RT Matheson, CL Leonardi, C Calderon, C Brodmerkel, ... Journal of Allergy and Clinical Immunology 133 (4), 1032-1040, 2014 | 343 | 2014 |
| Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids … EL Simpson, C Flohr, LF Eichenfield, T Bieber, H Sofen, A Taïeb, R Owen, ... Journal of the American Academy of Dermatology 78 (5), 863-871. e11, 2018 | 333 | 2018 |
| Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial K Papp, JC Cather, L Rosoph, H Sofen, RG Langley, RT Matheson, ... The Lancet 380 (9843), 738-746, 2012 | 322 | 2012 |
| Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study AB Kimball, KA Papp, Y Wasfi, D Chan, R Bissonnette, H Sofen, ... Journal of the European Academy of Dermatology and Venereology 27 (12), 1535 …, 2013 | 237 | 2013 |
| Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program … B Strober, D Thaçi, H Sofen, L Kircik, KB Gordon, P Foley, P Rich, C Paul, ... Journal of the American Academy of Dermatology 88 (1), 40-51, 2023 | 153 | 2023 |
| Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial R Bissonnette, L Iversen, H Sofen, CEM Griffiths, P Foley, R Romiti, ... British Journal of Dermatology 172 (5), 1395-1406, 2015 | 150 | 2015 |
| Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo … M Lebwohl, A Blauvelt, C Paul, H Sofen, J Węgłowska, V Piguet, D Burge, ... Journal of the American Academy of Dermatology 79 (2), 266-276. e5, 2018 | 138 | 2018 |
| Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from PHOENIX 1 P Rich, M Bourcier, H Sofen, S Fakharzadeh, Y Wasfi, Y Wang, ... British Journal of Dermatology 170 (2), 398-407, 2014 | 130 | 2014 |
| Noninvasive genomic detection of melanoma W Wachsman, V Morhenn, T Palmer, L Walls, T Hata, J Zalla, ... British Journal of Dermatology 164 (4), 797-806, 2011 | 127 | 2011 |
| The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic … R Bissonnette, C Maari, S Forman, N Bhatia, M Lee, J Fowler, S Tyring, ... British Journal of Dermatology 181 (4), 733-742, 2019 | 95 | 2019 |
| A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma H Sofen, KG Gross, LH Goldberg, H Sharata, TK Hamilton, B Egbert, ... Journal of the American Academy of Dermatology 73 (1), 99-105. e1, 2015 | 83 | 2015 |
| Impact of ustekinumab on health‐related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials L Guenther, C Han, P Szapary, B Schenkel, Y Poulin, M Bourcier, ... Journal of the European Academy of Dermatology and Venereology 25 (7), 851-857, 2011 | 82 | 2011 |
| The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study AB Gottlieb, RE Kalb, A Blauvelt, MP Heffernan, HL Sofen, LK Ferris, ... Journal of the American Academy of Dermatology 67 (4), 642-650, 2012 | 70 | 2012 |
| Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or … M Maurer, H Sofen, B Ortiz, F Kianifard, S Gabriel, JA Bernstein Journal of the European Academy of Dermatology and Venereology 31 (6), 1056-1063, 2017 | 58 | 2017 |
| Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis A Blauvelt, KA Papp, H Sofen, M Augustin, G Yosipovitch, N Katoh, ... Journal of the European Academy of Dermatology and Venereology 31 (6), 1004-1013, 2017 | 56 | 2017 |
